isoleucine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4129	73-32-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: isoleucine L-isoleucine	An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels. Molecular weight: 131.18 Formula: C6H13NO2 CLOGP: -1.76 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 63.32 ALOGS: -0.06 ROTB: 3

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal growth restriction	100.88	65.47	15	92	1125	2356853

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event

Pharmacologic Action:

None

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Sarcoidosis	contraindication	31541009	DOID:11335
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Hypercalcemia	contraindication	66931009	DOID:12678
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.51	acidic
pKa2	9.83	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D007532	MESH_DESCRIPTOR_UI
4018670	VUID
N0000146981	NUI
C0022192	UMLSCUI
D00065	KEGG_DRUG
04Y7590D77	UNII
6164	INN_ID
412426002	SNOMEDCT_US
6033	RXNORM
14971004	SNOMEDCT_US
4018670	VANDF
NOCODE	MMSL
003651	NDDF
DB00167	DRUGBANK_ID
CHEBI:17191	CHEBI
CHEMBL1233584	ChEMBL_ID
6306	PUBCHEM_CID
3311	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
NephrAmine	HUMAN PRESCRIPTION DRUG LABEL	10	0264-1909	INJECTION, SOLUTION	0.56 g	INTRAVENOUS	NDA	13 sections
ProcalAmine	HUMAN PRESCRIPTION DRUG LABEL	22	0264-1915	INJECTION	0.21 g	INTRAVENOUS	NDA	13 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3200	SOLUTION	749 mg	INTRAVENOUS	ANDA	13 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3205	SOLUTION	749 mg	INTRAVENOUS	ANDA	13 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	749 mg	INTRAVENOUS	ANDA	13 sections
FreAmine III	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9010	INJECTION, SOLUTION	0.69 g	INTRAVENOUS	NDA	13 sections
FreAmine III	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9011	INJECTION, SOLUTION	0.69 g	INTRAVENOUS	NDA	13 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9341	SOLUTION	0.82 g	INTRAVENOUS	NDA	12 sections
FreAmine HBC	HUMAN PRESCRIPTION DRUG LABEL	15	0264-9350	INJECTION, SOLUTION	0.76 g	INTRAVENOUS	NDA	13 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9361	SOLUTION	0.49 g	INTRAVENOUS	NDA	12 sections
HepatAmine	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9371	INJECTION, SOLUTION	0.90 g	INTRAVENOUS	NDA	13 sections
ProSol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0499	INJECTION, SOLUTION	1.08 g	INTRAVENOUS	NDA	15 sections
Clinisol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0502	INJECTION, SOLUTION	749 mg	INTRAVENOUS	ANDA	11 sections
Travasol	HUMAN PRESCRIPTION DRUG LABEL	15	0338-0644	INJECTION	600 mg	INTRAVENOUS	NDA	15 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-1083	INJECTION	165 mg	INTRAVENOUS	NDA	14 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-1089	INJECTION	255 mg	INTRAVENOUS	NDA	14 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-1091	INJECTION	255 mg	INTRAVENOUS	NDA	14 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-1093	INJECTION	255 mg	INTRAVENOUS	NDA	14 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-1095	INJECTION	255 mg	INTRAVENOUS	NDA	14 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-1099	INJECTION	300 mg	INTRAVENOUS	NDA	14 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-1101	INJECTION	300 mg	INTRAVENOUS	NDA	14 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	15	0338-1103	INJECTION	300 mg	INTRAVENOUS	NDA	14 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1107	INJECTION	165 mg	INTRAVENOUS	NDA	16 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1109	INJECTION	165 mg	INTRAVENOUS	NDA	16 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1113	INJECTION	255 mg	INTRAVENOUS	NDA	16 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1115	INJECTION	255 mg	INTRAVENOUS	NDA	16 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1119	INJECTION	255 mg	INTRAVENOUS	NDA	16 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1123	INJECTION	300 mg	INTRAVENOUS	NDA	16 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1125	INJECTION	300 mg	INTRAVENOUS	NDA	16 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-1127	INJECTION	300 mg	INTRAVENOUS	NDA	16 sections